Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Actinium Pharmaceuticals (ATNM – Research Report). The associated price target remains the same with $4.00.
Joseph Pantginis has given his Buy rating due to a combination of factors including Actinium Pharmaceuticals’ recent clinical advancements and strategic plans. The company has demonstrated significant progress in its radiotherapy pipeline, particularly with Actimab-A and Iomab-ACT, which have shown promising results in treating acute myeloid leukemia (AML) and solid tumors.
The feedback from key opinion leaders, such as Dr. Ehab Atallah, underscores the potential of Actimab-A as a transformative treatment. The company’s robust financial position, with a cash runway expected to last into mid-2027, further supports its ability to achieve both near-term and long-term milestones. The anticipated developments in 2025, including the initiation of a Phase 2/3 study and potential new data from solid tumor programs, contribute to the positive outlook for Actinium Pharmaceuticals, making it an attractive investment opportunity.
In another report released on March 17, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target.